Xingruida XDRTesamorelin
Ordered Tesamorelin from Xingruida XDR? Mail in a sample (US only) and let us test it for free.
Test my supplyRepeated purity misses drive the middling signal, including 95.779% and later 98.92%–99.21% results. Recent tested lots improved, but +29% overfill, missing batch IDs, and weak price/review corroboration keep the evidence mixed.
UK and Hong Kong filings resolve the storefront into a recent China-controlled export structure, with overdue compliance and unresolved HK directors. Infrastructure traces point to a sister peptide storefront sharing IP, nameservers and the same ASP/IIS template.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Xingruida XDR rows.
Cancel anytime
About Xingruida XDR test results from Finnrick
Xingruida XDR is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 92 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Xingruida XDR peptides in this dataset are BPC-157 (8 tests), GHK-Cu (9 tests) and Ipamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 92 recent tests.
Ordered Tesamorelin from Xingruida XDR? Mail in a sample (US only) and let us test it for free.
Test my supply